DE60210268D1 - Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten - Google Patents

Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten

Info

Publication number
DE60210268D1
DE60210268D1 DE60210268T DE60210268T DE60210268D1 DE 60210268 D1 DE60210268 D1 DE 60210268D1 DE 60210268 T DE60210268 T DE 60210268T DE 60210268 T DE60210268 T DE 60210268T DE 60210268 D1 DE60210268 D1 DE 60210268D1
Authority
DE
Germany
Prior art keywords
hydroxyestra
dien
esters
dimethyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60210268T
Other languages
English (en)
Other versions
DE60210268T2 (de
Inventor
P Blye
K Kim
Narasimha Rao
Kirk Acosta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/010293 external-priority patent/WO2001074839A2/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE60210268D1 publication Critical patent/DE60210268D1/de
Application granted granted Critical
Publication of DE60210268T2 publication Critical patent/DE60210268T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60210268T 2001-03-30 2002-03-29 Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten Expired - Lifetime DE60210268T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10293 2001-03-30
PCT/US2001/010293 WO2001074839A2 (en) 2000-03-31 2001-03-30 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use
PCT/US2002/009886 WO2003045398A1 (en) 2001-03-30 2002-03-29 Methods of making and pharmaceutical formulations comprising 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof

Publications (2)

Publication Number Publication Date
DE60210268D1 true DE60210268D1 (de) 2006-05-18
DE60210268T2 DE60210268T2 (de) 2006-12-07

Family

ID=21742454

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210268T Expired - Lifetime DE60210268T2 (de) 2001-03-30 2002-03-29 Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten

Country Status (7)

Country Link
EP (1) EP1379253B1 (de)
JP (1) JP2005510541A (de)
AT (1) ATE321557T1 (de)
DE (1) DE60210268T2 (de)
DK (1) DK1379253T3 (de)
ES (1) ES2261665T3 (de)
WO (1) WO2003045398A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA712312B (en) * 1970-04-28 1972-01-26 Ochsner Med Found Alton 4,14-estradiene compounds
TW548277B (en) * 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens

Also Published As

Publication number Publication date
WO2003045398A1 (en) 2003-06-05
DK1379253T3 (da) 2006-06-26
EP1379253A1 (de) 2004-01-14
WO2003045398A8 (en) 2004-02-19
ATE321557T1 (de) 2006-04-15
EP1379253B1 (de) 2006-03-29
DE60210268T2 (de) 2006-12-07
ES2261665T3 (es) 2006-11-16
JP2005510541A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
ATE231882T1 (de) 7alpha-(epsilon-aminoalkyl)-estratriene, verfahren zu deren herstellung, pharmazeutische präparate, die diese 7alpha-(epsilon-aminoalkyl)- estratriene enthalten sowie deren verwendung zur herstellung von arzneimitteln
ATE223413T1 (de) Neuartige verbindungen
DE59807213D1 (de) 11beta-halogen-7alpha-substituierte-estratriene, verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha-substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
DE69921941D1 (de) Verfahren zur Herstellung von pharmazeutischen Wirkstoffpartikeln
DE69718662D1 (de) Magnesium(-)hydroxycitrat, verfahren zur herstellung, anwendung und pharmazeutische zusammensetzungen, die sie enthalten
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ATE221531T1 (de) Kristallmodifikation des cdch, verfahren zu dessen herstellung und diese enthaltende pharmazeutische zubereitungen
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
DE59906017D1 (de) Benzocycloheptene, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
DE59610469D1 (de) Vorrichtung zur Verabreichung von Substanzen, insbesondere Inhalationspräparate
WO2001074839A3 (en) Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ATA900894A (de) Pharmazeutische kompositionen zum vorbeugen und heilen von krebserkrankungen und verfahren zu ihrer herstellung
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
ATE245445T1 (de) Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen
DE69908298D1 (de) Pentasaccharide, verfahren zu ihrer herstellung und pharmazeutische zubereitungen die sie enthalten
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
ATE247466T1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
DE68903059D1 (de) Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten.
ATE294181T1 (de) (3,4-a:3,4-c)carbazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE60210268D1 (de) Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition